{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:31:34Z","timestamp":1794493894124,"version":"4.9.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/s41584-023-01006-3","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:01:54Z","timestamp":1694149314000},"page":"640-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Mechanisms and rationale for uricase use in patients with gout"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-1202","authenticated-orcid":false,"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-1894","authenticated-orcid":false,"given":"Fernando","family":"P\u00e9rez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4419-0726","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"1006_CR1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/00325481.2016.1221732","volume":"128","author":"G Ruoff","year":"2016","unstructured":"Ruoff, G. & Edwards, N. L. Overview of serum uric acid treatment targets in gout: why less than 6 mg\/dL? Postgrad. Med. 128, 706\u2013715 (2016).","journal-title":"Postgrad. Med."},{"key":"1006_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3899\/jrheum.080938","volume":"36","author":"N Schlesinger","year":"2009","unstructured":"Schlesinger, N., Watson, D. J. & Norquist, J. M. Serum urate during acute gout. J. Rheumatol. 36, 1287\u20131289 (2009).","journal-title":"J. Rheumatol."},{"key":"1006_CR3","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/ar1909","volume":"8","author":"R Terkeltaub","year":"2006","unstructured":"Terkeltaub, R., Bushinsky, D. A. & Becker, M. A. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res. Ther. 8, S4 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"1006_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semnephrol.2004.09.002","volume":"25","author":"RJ Johnson","year":"2005","unstructured":"Johnson, R. J., Titte, S., Cade, J. R., Rideout, B. A. & Oliver, W. J. Uric acid, evolution and primitive cultures. Semin. Nephrol. 25, 3\u20138 (2005).","journal-title":"Semin. Nephrol."},{"key":"1006_CR5","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/rheumatology\/keq204","volume":"49","author":"B \u00c1lvarez-Lario","year":"2010","unstructured":"\u00c1lvarez-Lario, B. & Macarr\u00f3n-Vicente, J. Uric acid and evolution. Rheumatology 49, 2010\u20132015 (2010).","journal-title":"Rheumatology"},{"key":"1006_CR6","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1073\/pnas.1320393111","volume":"111","author":"JT Kratzer","year":"2014","unstructured":"Kratzer, J. T. et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc. Natl Acad. Sci. USA 111, 3763\u20133768 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1006_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.140588","volume":"42","author":"N Rashid","year":"2015","unstructured":"Rashid, N. et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J. Rheumatol. 42, 504\u2013512 (2015).","journal-title":"J. Rheumatol."},{"key":"1006_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald, J. D. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 72, 744\u2013760 (2020).","journal-title":"Arthritis Care Res."},{"key":"1006_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29\u201342 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., P\u00e9trilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"1006_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero-Beites, A. M. & Ruibal, A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47, 356\u2013360 (2002).","journal-title":"Arthritis Rheum."},{"key":"1006_CR12","first-page":"1888","volume":"34","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz, F., Martin, I. & Canteli, B. J. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J. Rheumatol. 34, 1888\u20131893 (2007).","journal-title":"J. Rheumatol."},{"key":"1006_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/rheumatology\/key303","volume":"58","author":"E Ebstein","year":"2019","unstructured":"Ebstein, E. et al. Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study. Rheumatology 58, 410\u2013417 (2019).","journal-title":"Rheumatology"},{"key":"1006_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/14397595.2020.1825053","volume":"31","author":"CSK Chui","year":"2021","unstructured":"Chui, C. S. K. et al. Volumetric reduction and dissolution prediction of monosodium urate crystal during urate-lowering therapy \u2013 a study using dual-energy computed tomography. Mod. Rheumatol. 31, 875\u2013884 (2021).","journal-title":"Mod. Rheumatol."},{"key":"1006_CR15","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1136\/ard.2008.099713","volume":"68","author":"HK Choi","year":"2009","unstructured":"Choi, H. K. et al. Dual energy computed tomography in tophacheous gout. Ann. Rheum. Dis. 68, 1609\u20131612 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/annrheumdis-2014-206397","volume":"74","author":"N Dalbeth","year":"2015","unstructured":"Dalbeth, N. et al. Urate crystal deposition in asymptomatic hyperuricemia and symptomatic gout: a dual energy CT study. Ann. Rheum. Dis. 74, 908\u2013911 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR17","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1136\/ard.2010.128454","volume":"69","author":"N Schlesinger","year":"2010","unstructured":"Schlesinger, N. & Thiele, R. G. The pathogenesis of bone erosions in gouty arthritis. Ann. Rheum. Dis. 69, 1907\u20131912 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1136\/annrheumdis-2013-204273","volume":"74","author":"N Dalbeth","year":"2015","unstructured":"Dalbeth, N. et al. Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study. Ann. Rheum. Dis. 74, 1030\u20131036 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018431","volume":"98","author":"D Shi","year":"2019","unstructured":"Shi, D. et al. Relationship between urate within tophus and bone erosion according to the anatomic location of urate deposition in gout: a quantitative analysis using dual-energy CT volume measurements. Medicine 98, e18431 (2019).","journal-title":"Medicine"},{"key":"1006_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/rheumatology\/keq335","volume":"50","author":"N Dalbeth","year":"2011","unstructured":"Dalbeth, N. et al. Development of a computed tomography method of scoring bone erosion in patients with gout: validation and clinical implications. Rheumatology 50, 410\u2013416 (2011).","journal-title":"Rheumatology"},{"key":"1006_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000075","volume":"1","author":"EG Araujo","year":"2015","unstructured":"Araujo, E. G. et al. Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD Open\u00a01, e000075 (2015).","journal-title":"RMD Open"},{"key":"1006_CR22","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s10067-017-3729-z","volume":"36","author":"DV Modjinou","year":"2017","unstructured":"Modjinou, D. V. et al. Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking. Clin. Rheumatol. 36, 2101\u20132107 (2017).","journal-title":"Clin. Rheumatol."},{"key":"1006_CR23","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1093\/rheumatology\/keac173","volume":"61","author":"N Dalbeth","year":"2022","unstructured":"Dalbeth, N. et al. Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodeling during pegloticase plus methotrexate co-therapy. Rheumatology 61, 4898\u20134904 (2022).","journal-title":"Rheumatology"},{"key":"1006_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13075-018-1782-x","volume":"20","author":"BF Mandell","year":"2018","unstructured":"Mandell, B. F., Yeo, A. E. & Lipsky, P. E. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Arthritis Res. Ther. 20, 286 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"1006_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui, M. et al. The British Society for Rheumatology guideline for the management of gout. Rheumatology 56, e1\u2013e20 (2017).","journal-title":"Rheumatology"},{"key":"1006_CR26","doi-asserted-by":"publisher","first-page":"o1754","DOI":"10.1136\/bmj.o1754","volume":"378","author":"J Neilson","year":"2022","unstructured":"Neilson, J., Bonnon, A., Dickson, A., Roddy, E. & Guideline Committee. Gout: diagnosis and management \u2013 summary of NICE guidance. BMJ 378, o1754 (2022).","journal-title":"BMJ"},{"key":"1006_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jbspin.2012.01.004","volume":"79","author":"RP Garay","year":"2012","unstructured":"Garay, R. P., El-Gewely, M. R., Labaune, J. P. & Richette, P. Therapeutic perspectives on uricases for gout. Joint Bone Spine 79, 237\u2013242 (2012).","journal-title":"Joint Bone Spine"},{"key":"1006_CR28","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky, P. E. et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res. Ther. 16, R60 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"1006_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy, J. S. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306, 711\u2013720 (2011).","journal-title":"JAMA"},{"key":"1006_CR30","unstructured":"FDA. Highlights of prescribing information: Elitek. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103946s5083lbl.pdf (2009)."},{"key":"1006_CR31","unstructured":"European Medicines Agency. Fasturtec (rasburicase). European Medicines Agency https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fasturtec (2023)."},{"key":"1006_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40264-014-0255-7","volume":"38","author":"KC Allen","year":"2015","unstructured":"Allen, K. C. et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf. 38, 183\u2013187 (2015).","journal-title":"Drug Saf."},{"key":"1006_CR33","first-page":"2093","volume":"34","author":"P Richette","year":"2007","unstructured":"Richette, P., Bri\u00e8re, C., Hoenen-Clavert, V., Loeuille, D. & Bardin, T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J. Rheumatol. 34, 2093\u20132098 (2007).","journal-title":"J. Rheumatol."},{"key":"1006_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","volume":"60","author":"MR Sherman","year":"2008","unstructured":"Sherman, M. R., Saifer, M. G. & Perez-Ruiz, F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev. 60, 59\u201368 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1006_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd3349","volume":"10","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger, N., Yasothan, U. & Kirkpatrick, P. Pegloticase. Nat. Rev. Drug Discov. 10, 17\u201318 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1006_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/BOR.0b013e3282f4eff5","volume":"20","author":"E Fels","year":"2008","unstructured":"Fels, E. & Sundy, J. S. Refractory gout: What is it and what to do about it? Curr. Opin. Rheumatol. 20, 198\u2013202 (2008).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1006_CR37","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty, M. et al. Gout: why is this curable disease so seldom cured? Ann. Rheum. Dis. 71, 1765\u20131770 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR38","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.semarthrit.2020.04.011","volume":"50","author":"N Schlesinger","year":"2020","unstructured":"Schlesinger, N. & Lipsky, P. E. Pegloticase treatment of chronic refractory gout: update on efficacy and safety. Semin. Arthritis Rheum. 50, S31\u2013S38 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"1006_CR39","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","volume":"72","author":"MA Becker","year":"2013","unstructured":"Becker, M. A. et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann. Rheum. Dis. 72, 1469\u20131474 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR40","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker, M. A. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 52, 916\u2013923 (2005).","journal-title":"Arthritis Rheum."},{"key":"1006_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta, E. et al. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA 328, 440\u2013450 (2022).","journal-title":"JAMA"},{"key":"1006_CR42","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar4500","volume":"16","author":"MS Hershfield","year":"2014","unstructured":"Hershfield, M. S. et al. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res. Ther. 16, R63 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"1006_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","volume":"20","author":"HS Baraf","year":"2014","unstructured":"Baraf, H. S., Yood, R. A., Ottery, F. D., Sundy, J. S. & Becker, M. A. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J. Clin. Rheumatol. 20, 427\u2013432 (2014).","journal-title":"J. Clin. Rheumatol."},{"key":"1006_CR44","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1345\/aph.1G272","volume":"39","author":"LA Browning","year":"2005","unstructured":"Browning, L. A. & Kruse, J. A. Hemolysis and methemoglobinemia are secondary to rasburicase administration. Ann. Pharmacother. 39, 1932\u20131935 (2005).","journal-title":"Ann. Pharmacother."},{"key":"1006_CR45","unstructured":"Dean, L. & Kane M. in Medical Genetics Summaries (eds Pratt V. M. et al.) 489\u2013498 (National Center for Biotechnology Information, 2020)."},{"key":"1006_CR46","unstructured":"FDA. Highlights of prescribing information: Krystexxa. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125293s104lbl.pdf (2022)."},{"key":"1006_CR47","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3899\/jrheum.200460","volume":"48","author":"JK Botson","year":"2021","unstructured":"Botson, J. K. et al. Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR). J. Rheumatol. 48, 767\u2013774 (2021).","journal-title":"J. Rheumatol."},{"key":"1006_CR48","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/annrheumdis-2020-eular.3893","volume":"79","author":"B Lamoreaux","year":"2020","unstructured":"Lamoreaux, B., Francis-Sedlak, M., Svensson, K. & Holt, R. Immunomodulation co-therapy with pegloticase: database trends 2014\u20132019 [abstract OP0173]. Ann. Rheum. Dis. 79, 108 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR49","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/art.41731","volume":"73","author":"PP Khanna","year":"2021","unstructured":"Khanna, P. P. et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 73, 1523\u20131532 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1006_CR50","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/annrheumdis-2020-eular.4642","volume":"79","author":"H Rainey","year":"2020","unstructured":"Rainey, H., Baraf, H. S. B., Yeo, A. & Lipsky, P. E. Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout [abstract THU0410]. Ann. Rheum. Dis. 79, 442\u2013443 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","volume":"51","author":"RT Keenan","year":"2021","unstructured":"Keenan, R. T. et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin. Arthritis Rheum. 51, 347\u2013352 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1006_CR52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/acr2.11578","volume":"5","author":"JK Botson","year":"2023","unstructured":"Botson, J. K. et al. A randomized, double-blind, placebo-controlled multicenter efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: 12-month findings. ACR Open Rheumatol.\u00a05, 407\u2013418 (2023).","journal-title":"ACR Open Rheumatol."},{"key":"1006_CR53","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/ar4318","volume":"15","author":"HS Baraf","year":"2013","unstructured":"Baraf, H. S. et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res. Ther. 15, R137 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1006_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.42335","volume":"75","author":"JK Botson","year":"2023","unstructured":"Botson, J. K. et al. A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings. Arthritis Rheumatol. 75, 293\u2013304 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1006_CR55","first-page":"1807","volume":"74","author":"N Dalbeth","year":"2022","unstructured":"Dalbeth, N. et al. Reduction in monosodium urate crystal deposit volume during the MIRROR RCT trial in patients treated with pegloticase plus methotrexate co-therapy: a serial dual-energy computed tomography (DECT) analysis [abstract]. Arthritis Rheumatol. 74, 1807 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1006_CR56","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3899\/jrheum.111375","volume":"39","author":"V Strand","year":"2012","unstructured":"Strand, V., Khanna, D., Singh, J. A., Forsythe, A. & Edwards, N. L. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J. Rheumatol. 39, 1450\u20131457 (2012).","journal-title":"J. Rheumatol."},{"key":"1006_CR57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/01.HYP.0000150784.92944.9a","volume":"45","author":"J Sundstr\u00f6m","year":"2005","unstructured":"Sundstr\u00f6m, J. et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45, 28\u201333 (2005).","journal-title":"Hypertension"},{"key":"1006_CR58","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1056\/NEJM196609012750902","volume":"275","author":"PJ Cannon","year":"1996","unstructured":"Cannon, P. J., Stason, W. B., Demartini, F. E., Sommers, S. C. & Laragh, J. H. Hyperuricemia in primary and renal hypertension. N. Engl. J. Med. 275, 457\u2013464 (1966).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR59","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","volume":"69","author":"M Kuwabara","year":"2017","unstructured":"Kuwabara, M. et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension 69, 1036\u20131044 (2017).","journal-title":"Hypertension"},{"key":"1006_CR60","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","volume":"60","author":"B Soletsky","year":"2012","unstructured":"Soletsky, B. & Feig, D. I. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 60, 1148\u20131156 (2012).","journal-title":"Hypertension"},{"key":"1006_CR61","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jama.300.8.924","volume":"300","author":"DI Feig","year":"2008","unstructured":"Feig, D. I., Soletsky, B. & Johnson, R. J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300, 924\u2013932 (2008).","journal-title":"JAMA"},{"key":"1006_CR62","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/art.41749","volume":"73","author":"AL Gaffo","year":"2021","unstructured":"Gaffo, A. L. et al. Effect of serum urate lowering with allopurinol on blood pressure in young adults: a randomized, controlled, crossover trial. Arthritis Rheumatol. 73, 1514\u20131522 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1006_CR63","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2215\/CJN.10771016","volume":"12","author":"CJ McMullan","year":"2017","unstructured":"McMullan, C. J., Borgi, L., Fisher, N., Curhan, G. & Forman, J. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 12, 807\u2013816 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1006_CR64","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria, A. et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N. Engl. J. Med. 382, 2493\u20132503 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR65","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve, S. V. et al. Effects of allopurinol on the progression of chronic kidney disease. N. Engl. J. Med. 382, 2504\u20132513 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR66","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","volume":"400","author":"IS Mackenzie","year":"2022","unstructured":"Mackenzie, I. S. et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400, 1195\u20131205 (2022).","journal-title":"Lancet"},{"key":"1006_CR67","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","volume":"392","author":"Doherty","year":"2018","unstructured":"Doherty et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392, 1403\u20131412 (2018).","journal-title":"Lancet"},{"key":"1006_CR68","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White, W. B. et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378, 1200\u20131210 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR69","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie, I. S. et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 396, 1745\u20131757 (2020).","journal-title":"Lancet"},{"key":"1006_CR70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1161\/HYPERTENSIONAHA.119.12727","volume":"74","author":"RJ Johnson","year":"2019","unstructured":"Johnson, R. J., Choi, H. K., Yeo, A. E. & Lipsky, P. E. Pegloticase treatment significantly decreases blood pressure in patients with chronic gout. Hypertension 74, 95\u2013101 (2019).","journal-title":"Hypertension"},{"key":"1006_CR71","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41440-020-0481-6","volume":"43","author":"M Lanaspa","year":"2020","unstructured":"Lanaspa, M. et al. Uric acid and hypertension. Hypertens. Res. 43, 832\u2013834 (2020).","journal-title":"Hypertens. Res."},{"key":"1006_CR72","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.kint.2020.08.024","volume":"99","author":"T Bardin","year":"2021","unstructured":"Bardin, T. et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 99, 218\u2013226 (2021).","journal-title":"Kidney Int."},{"key":"1006_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/gucdd1010004","volume":"1","author":"T Bardin","year":"2023","unstructured":"Bardin, T., Letavernier, E. & Correas, J.-M. The gouty kidney: a reappraisal. Gout Urate Cryst. Depos. Dis. 1, 25\u201336 (2023).","journal-title":"Gout Urate Cryst. Depos. Dis."},{"key":"1006_CR74","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","volume":"17","author":"LK Stamp","year":"2021","unstructured":"Stamp, L. K. et al. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat. Rev. Rheumatol. 17, 633\u2013641 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1006_CR75","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3109\/03009741003742797","volume":"39","author":"CF Kuo","year":"2010","unstructured":"Kuo, C. F. et al. Gout and risk of non-alcoholic fatty liver disease. Scand. J. Rheumatol. 39, 466\u2013471 (2010).","journal-title":"Scand. J. Rheumatol."},{"key":"1006_CR76","doi-asserted-by":"publisher","first-page":"264","DOI":"10.17235\/reed.2019.5965\/2018","volume":"111","author":"CM Fern\u00e1ndez Rodr\u00edguez","year":"2019","unstructured":"Fern\u00e1ndez Rodr\u00edguez, C. M. et al. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). Rev. Esp. Enferm. Dig. 111, 264\u2013269 (2019).","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"1006_CR77","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.dsx.2018.10.001","volume":"13","author":"S Sandra","year":"2019","unstructured":"Sandra, S. et al. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from a tertiary referral center. Diabetes Metab. Syndr. 13, 424\u2013428 (2019).","journal-title":"Diabetes Metab. Syndr."},{"key":"1006_CR78","first-page":"60","volume":"41","author":"N Schlesinger","year":"2023","unstructured":"Schlesinger, N., Rustgi, V. K., Yeo, A. E. & Lipsky, P. E. Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients. Clin. Exp. Rheumatol. 41, 60\u201366 (2023).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1006_CR79","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","volume":"12","author":"G Szabo","year":"2015","unstructured":"Szabo, G. & Petrasek, J. Inflammasome activation and function in liver disease. Nat. Rev. Gastroenterol. Hepatol. 12, 387\u2013400 (2015).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1006_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27945-7","volume":"13","author":"E Sands","year":"2022","unstructured":"Sands, E. et al. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nat. Commun. 13, 272 (2022).","journal-title":"Nat. Commun."},{"key":"1006_CR81","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/acr.23480","volume":"70","author":"R Azeem","year":"2018","unstructured":"Azeem, R. et al. Initial phase 2 clinical data of SEL-212 in symptomatic gout patients: monthly dosing of a pegylated uricase (pegadricase) with Svp-rapamycin enables sustained reduction of acute gout flares [abstract]. Arthritis Rheumatol. 70, 1294 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1006_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead333","author":"HSB Baraf","year":"2023","unstructured":"Baraf, H. S. B. et al. The COMPARE head-to-head, randomised-controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR\u2122) versus pegloticase for refractory gout. Rheumatology\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/kead333 (2023).","journal-title":"Rheumatology"},{"key":"1006_CR83","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1136\/annrheumdis-2023-eular.7084","volume":"82","author":"HSB Baraf","year":"2023","unstructured":"Baraf, H. S. B. et al. Safety & efficacy of SEL-212 in patients with gout refractory to coventional treatment: outcomes from two randomized, double blind, placebo-controlled, multicenter phase III studies [abstract LB0002]. Ann. Rheum. Dis. 82, 200\u2013201 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR84","doi-asserted-by":"publisher","first-page":"569215","DOI":"10.3389\/fmed.2020.569215","volume":"7","author":"K Pierzynowska","year":"2020","unstructured":"Pierzynowska, K. et al. Oral treatment with an engineered uricase, ALLN-346, reduces hyperuricemia, and uricosuria in urate oxidase-deficient mice. Front. Med. 7, 569215 (2020).","journal-title":"Front. Med."},{"key":"1006_CR85","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/annrheumdis-2022-eular.1662","volume":"81","author":"R Terkeltaub","year":"2022","unstructured":"Terkeltaub, R. et al.Safety and efficacy of ALLN-346 oral enzyme therapy in patients with hyperuricemia and chronic kidney disease (CKD): results of the phase 2A study 201 [abstract POS1157]. Ann. Rheum. Dis. 81, 907 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR86","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/pbi.12702","volume":"15","author":"U Hanania","year":"2017","unstructured":"Hanania, U. et al. Establishment of a tobacco BY2 cell line devoid of plant-specific xylose and fucose as a platform for the production of biotherapeutic proteins. Plant. Biotechnol. J. 15, 1120\u20131129 (2017).","journal-title":"Plant. Biotechnol. J."},{"key":"1006_CR87","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.taap.2015.06.004","volume":"287","author":"J Atsmon","year":"2015","unstructured":"Atsmon, J. et al. Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R. Toxicol. Appl. Pharmacol. 287, 202\u2013209 (2015).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1006_CR88","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3899\/jrheum.150345","volume":"43","author":"N Schlesinger","year":"2016","unstructured":"Schlesinger, N., Etzel, C., Greenberg, J., Kremer, J. & Harrold, L. Gout flare prophylaxis evaluated according to the 2012 American College of Rheumatology (ACR) guidelines: analysis from the CORRONA Gout Registry. J. Rheumatol. 43, 924\u2013930 (2016).","journal-title":"J. Rheumatol."},{"key":"1006_CR89","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.semarthrit.2012.03.010","volume":"42","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger, N. Treatment of chronic gouty arthritis: it\u2019s not just about urate-lowering therapy. Semin. Arthritis Rheum. 42, 155\u2013165 (2012).","journal-title":"Semin. Arthritis Rheum."},{"key":"1006_CR90","unstructured":"FDA. Highlights of prescribing information: Colcrys. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022353lbl.pdf (2009)."},{"key":"1006_CR91","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of gout. European Medicines Agency https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-gout-first-version_en.pdf (2019)."},{"key":"1006_CR92","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/ard.2010.144063","volume":"70","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger, N. et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol therapy: results of a double-blind, randomised study. Ann. Rheum. Dis. 70, 1264\u20131271 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1006_CR93","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/rheumatology\/ket114","volume":"52","author":"E Mitha","year":"2013","unstructured":"Mitha, E. et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology 52, 1285\u20131292 (2013).","journal-title":"Rheumatology"},{"key":"1006_CR94","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40744-019-0151-9","volume":"6","author":"RT Keenan","year":"2019","unstructured":"Keenan, R. T., Baraf, H. S. B. & LaMoreaux, B. Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase. Rheumatol. Ther. 6, 299\u2013304 (2019).","journal-title":"Rheumatol. Ther."},{"key":"1006_CR95","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/mds.22139","volume":"23","author":"I Schlesinger","year":"2008","unstructured":"Schlesinger, I. & Schlesinger, N. Uric acid in Parkinson\u2019s disease. Mov. Disord. 23, 1653\u20131657 (2008).","journal-title":"Mov. Disord."},{"key":"1006_CR96","doi-asserted-by":"publisher","first-page":"msab312","DOI":"10.1093\/molbev\/msab312","volume":"39","author":"Z Li","year":"2022","unstructured":"Li, Z., Hoshino, Y., Tran, L. & Gaucher, E. A. Phylogenetic articulation of uric acid evolution in mammals and how it informs a therapeutic uricase. Mol. Biol. Evol. 39, msab312 (2022).","journal-title":"Mol. Biol. Evol."},{"key":"1006_CR97","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF00163854","volume":"34","author":"XW Wu","year":"1992","unstructured":"Wu, X. W., Muzny, D. M., Lee, C. C. & Caskey, C. T. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J. Mol. Evol. 34, 78\u201384 (1992).","journal-title":"J. Mol. Evol."},{"key":"1006_CR98","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1056\/NEJM198501313120505","volume":"312","author":"SB Eaton","year":"1985","unstructured":"Eaton, S. B. & Konner, M. Paleolithic nutrition. A consideration of its nature and current implications. N. Engl. J. Med. 312, 283\u2013289 (1985).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003733","volume":"3","author":"J Powles","year":"2013","unstructured":"Powles, J. et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 3, e003733 (2013).","journal-title":"BMJ Open"},{"key":"1006_CR100","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000028589.66335.AA","volume":"40","author":"S Watanabe","year":"2002","unstructured":"Watanabe, S. et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40, 355\u2013360 (2002).","journal-title":"Hypertension"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01006-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:02:41Z","timestamp":1695373361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01006-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01006-3","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"18 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.S. declares that she has received a grant from Olatec and has been on advisory boards and acted as a consultant for ANI, Horizon Pharma, Novartis, Protalix and SOBI. F.P.-R. declares that he is an adviser for Anlylam, Arthriti and Protalix; a speaker for Menarini Central America; a member of Data and\u00a0Safety Monitoring Board\u00a0(DMSB) for Selecta\/SOBI; does editorial work for Springer Healthcare, Wolters-Kluwer, Exploration Publications and the Spanish Foundation for Rheumatology; and has received grants from the Cruces Rheumatology Association. F.L. declares that he has been on advisory boards for Horizon Pharma, Novartis France and Olatec; is a member of DMSB for Olatec; does editorial work for Elsevier; is a CME speaker for Mayoly-Spindler, Menarini Central America and Novartis; and has received unrestricted educational grants from Horizon Pharma, Mayoly-Spindler, Novartis, Olatec and SOBI for the European Crystal Network workshops.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}